Skip to main content
S 334 109th Congress Senate

Pharmaceutical Market Access and Drug Safety Act of 2005

Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes.

Introduced: February 9, 2005 See on congress.gov
Health Accreditation (Medical care)Administrative feesAdministrative procedureAdministrative remedies
More subjectsShow fewer subjects
AustraliaBusiness recordsCanadaCivil Rights and Liberties, Minority IssuesCivil actions and liabilityCommerceCongressCongressional reporting requirementsConsumer educationContractsCrime and Law EnforcementCustoms administrationDamagesDefective productsDepartment of Health and Human ServicesDirectoriesDrug advertisingDrug approvalsDrug industryDrugsEast AsiaEconomics and Public FinanceEducationElectronic commerceElectronic data interchangeElectronic government informationEuropeEuropean UnionEvidence (Law)Export controlsExportsFederal Trade CommissionFederal-state relationsFinance and Financial SectorFines (Penalties)Food and Drug Administration (FDA)Foreign Trade and International FinanceForfeitureFraudGovernment Operations and PoliticsGovernment paperworkGovernment publicityGovernmental investigationsHigher educationIdentification devicesImport restrictionsImportsIndependent regulatory commissionsInjunctionsIntellectual propertyInteractive mediaInternetJapanLabelingLawLiability (Law)LicensesMedical associationsMedical educationMedical recordsMedical testsNew ZealandOceaniaPackagingParties to actionsPatent infringementPatentsPharmaceutical researchPharmaciesPharmacistsPhysical examinationsPrescription pricingPrice discriminationProduct counterfeitingRestrictive trade practicesRight of privacyScience, Technology, CommunicationsSurety and fidelitySwitzerlandTelephoneUser chargesWeb sitesWholesale trade
This bill died when the 109th Congress ended
It never became law before the 109th Congress (2005–2006) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 19, 2005
Committee on Health, Education, Labor, and Pensions. Hearings held. Hearings printed: S.Hrg. 109-143.
Feb 10, 2005
Sponsor introductory remarks on measure. (CR S1253-1254)
Feb 9, 2005
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 9, 2005
Sponsor introductory remarks on measure. (CR S1206)
Feb 9, 2005
Introduced in Senate
Jan 26, 2005
Sponsor introductory remarks on measure. (CR S540-541)
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action April 19, 2005

Committee on Health, Education, Labor, and Pensions. Hearings held. Hearings printed: S.Hrg. 109-143.

 Plain-English summary Congressional Research Service

Pharmaceutical Market Access and Drug Safety Act of 2005 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise provisions governing the importation of prescription drugs. Waives the limitation on importation of prescription drugs that have been exported from the United States.

Prohibits the importation of a qualifying drug unless such drug is imported by: (1) a registered importer; or (2) an individual for personal use.

Establishes registration conditions for importers and exporters. Requires the Secretary to inspect places of business, verify chains of custody, inspect facilities, and determine compliance with registration conditions.

Sets forth provisions governing the importation of qualifying drugs that are different from U.S. label drugs, including standards for judging such differences.

Prohibits manufacturers from: (1) discriminating against registered exporters or importers; (2) causing there to be a difference in a prescription drug distributed in the United States and one distributed in a permitted country; (3) engaging in actions to restrict, prohibit, or delay the importation of a qualifying drug; or (4) engaging in any action that the Federal Trade Commission (FTC) determines discriminates against a person that engages or attempts to engage in the importation of a qualifying drug.

States that the resale in the United States of prescription drugs that were properly sold abroad is not patent infringement.

Requires the Secretary to educate consumers regarding prescription drug importation.

Sets forth provisions governing the sale of prescription drugs through an Internet site. Includes the dispensing or selling of a prescription drug in violation of this Act as a prohibited act under FFDCA.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 334: Pharmaceutical Market Access and Drug Safety Act of 2005. 109th Congress. Open America. https://openamerica.io/bill/109-S-334/
MLA
"S. 334: Pharmaceutical Market Access and Drug Safety Act of 2005." 109th Congress, 2026, Open America, https://openamerica.io/bill/109-S-334/.
Bluebook (legal)
S. 334, 109th Cong. (2026), https://openamerica.io/bill/109-S-334/.
Markdown link
[S. 334: Pharmaceutical Market Access and Drug Safety Act of 2005](https://openamerica.io/bill/109-S-334/)
Report a problem